Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

Share Price is delayed by 15 minutes
Get Live Data
114.00    2.50 (2.24%)
Bid:
112.00
Ask:
116.00
Spread: 4.00 (3.571%)
Market Cap: £68.59m
IGP Live PriceLast checked at - London Stock Exchange

Intraday Intercede Share Chart

Trading Update & Contract Win

5 Apr 2022 07:00

RNS Number : 2229H
Intercede Group PLC
05 April 2022
 

 

 

 

5 April 2022

 

INTERCEDE GROUP plc

('Intercede', the 'Company' or the 'Group')

 

Trading Update & Contract Win

 

Intercede, the leading specialist in digital identity, credential management and secure mobility, announces that, subject to the completion of the year end audit, revenues for the year ended 31 March 2022 are expected to be in the region of £9.9-10.0m, which is approximately 9% lower than the previous financial year (4% lower at constant exchange rates).

 

Whilst the number of new deployments is the highest in recent years, delays have been experienced with a number of large new opportunities that had been expected to close this year and consequently there has not been a substantial license order received during the year ended 31 March 2022. Furthermore, COVID-19 has continued to impact trading outside the US market.

 

Although revenues are lower than market expectations, strong progress has been made during the past year with all other aspects of the business. MyID v12 has been launched which includes FIDO functionality thereby enabling the Group to substantially increase its addressable market following the long-awaited issue of FIPS 201-3 which finally took place in February 2022. New partnerships have also been formed during the year in Europe, the US, ASEAN, Latin America and Africa which is critical for the Group's future growth prospects.

 

Having increased the value of annual recurring revenues from Support & Maintenance plus repeatable Professional Services revenues to reach the point where they now largely cover annual fixed costs, the Group is expected to remain profitable. As at 31 March 2022, gross cash balances totalled £7.8m (2021: £8.0m).

 

Further detail will be provided within Intercede's final results which are expected to be published in June 2022.

 

Contract Win

 

Further to the announcement of 2 February 2022, Intercede announces that it received an initial order totalling $0.3m immediately prior to the year end from another large and prestigious US Federal Agency, a portion of which will be recognised in the year ended 31 March 2022.

 

The contract relates to the supply of Intercede's MyID credential management software to deploy digital identities to mobile devices in the form of derived PIV credentials, compliant with US government security standards FIPS 201 and SP 800-157. Intercede will work closely with its new partner to commence the migration from a competitor.

 

 

ENQUIRIES

 

Intercede Group plc  Tel. +44 (0)1455 558 111Klaas van der Leest, Chief Executive

Andrew Walker, Finance Director

 

finnCap Tel. +44 (0)20 7220 0500Simon Hicks / Fergus Sullivan, Corporate Finance

Tim Redfern / Charlotte Sutcliffe, ECM

 

 

 

About Intercede

 

Intercede is a cybersecurity company specialising in digital identities, derived credentials and access control, enabling digital trust in a mobile world.

 

Headquartered in the UK, with offices in the US, we believe in a connected world in which people and technology are free to exchange information securely, and complex insecure passwords become a thing of the past.

 

Our vision is to make the highest levels of cybersecurity available to organizations and consumers alike, solving complexity and scalability issues by managing high volumes of digital credentials.

 

We have been delivering trusted solutions to high profile customers for over 20 years. Our team of experts has deployed millions of identities to governments, most of the largest aerospace and defence corporations, and major financial services and healthcare organizations, as well as leading telecommunications, cloud services and information technology firms, providing industry-leading employee and customer credential management systems.

 

For more information visit: www.intercede.com

 

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the company's obligations under Article 17 of MAR.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUPUCUCUPPGMC
Date   Source Headline
20th May 20267:00 amRNS-RPartnership with OneSpan
19th May 20267:00 amRNSNotice of Results and Investor Presentation
11th May 20262:50 pmRNSShare Incentive Scheme
21st Apr 20267:00 amRNSNew Contract Upsell Orders and Renewal
9th Apr 20267:00 amRNSTrading Update, Renewals and New Contract Orders
17th Mar 20267:00 amRNSYear End Trading Update
17th Mar 20267:00 amRNSYear End Trading Update
9th Feb 202612:55 pmRNSHolding(s) in Company
15th Jan 202610:44 amRNSExercise of Options & Total Voting Rights
24th Dec 20257:00 amRNSExercise of Options & Total Voting Rights
2nd Dec 20251:05 pmRNSHolding(s) in Company
25th Nov 20257:01 amRNSNew Contract Awards and Renewals
25th Nov 20257:00 amRNSHalf-year Report
22nd Oct 20252:15 pmRNSNotice of Interim Results & Investor Presentation
13th Oct 20257:00 amRNSExercise of Options, PDMR Shareholding & TVR
10th Oct 202510:25 amRNSDirector/PDMR Shareholding
9th Oct 20251:02 pmRNSDirector/PDMR Shareholding
9th Oct 20257:00 amRNSTrading Update, New Contract awards and Renewals
25th Sep 20251:03 pmRNSResult of AGM
22nd Sep 20257:00 amRNSNon-Executive Director Change
22nd Aug 20257:00 amRNSIssue of Equity & Total Voting Rights
12th Aug 20257:00 amRNSNotice of AGM and release of Annual Report 2025
24th Jul 20257:00 amRNS-RFirst CMS to support FIDO enterprise attestation
22nd Jul 20257:00 amRNSGrowth Share Scheme Vesting and Award Allocation
3rd Jul 20257:00 amRNSNew Contract Orders and Renewals
25th Jun 20256:01 pmRNSDirector/PDMR Shareholding
25th Jun 20257:00 amRNSDirector/PDMR Shareholding
24th Jun 20257:00 amRNSFinal Results
22nd May 20253:14 pmRNSNotice of Results & Investor Presentation
7th May 20257:00 amRNSShare Incentive Scheme
1st May 20257:00 amRNS-RIntercede Collaborates with Microsoft and Yubico
8th Apr 20257:00 amRNSTrading Update
2nd Apr 20257:00 amRNSMomentum maintained with New Contract Orders
31st Mar 202511:48 amRNSHolding(s) in Company
12th Mar 20251:54 pmRNSDirector/PDMR Shareholding
12th Mar 20257:00 amRNSContinued Momentum with New Contract Orders
8th Jan 20257:00 amRNSContract Orders and Renewals
24th Dec 20247:00 amRNSTransaction in Own Shares
23rd Dec 20247:00 amRNSTransaction in Own Shares
19th Dec 20247:00 amRNSTransaction in Own Shares
13th Dec 20247:00 amRNSTransaction in Own Shares
11th Dec 20247:00 amRNSTransaction in Own Shares
10th Dec 20247:00 amRNSTransaction in Own Shares
5th Dec 20247:00 amRNSTransaction in Own Shares
2nd Dec 20247:00 amRNSTransaction in Own Shares
29th Nov 20247:00 amRNSTransaction in Own Shares
28th Nov 20247:00 amRNSTransaction in Own Shares
27th Nov 20247:00 amRNSTransaction in Own Shares
26th Nov 20247:00 amRNSHalf-year Report
26th Nov 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.